Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcella Petrone

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Bioorganic & Medicinal Chemistry Letters|November 3, 2006
5-HT2C antagonists based on fused heterotricyclic templates: design, synthesis and biological evaluationDieter Hamprecht, Fabrizio Micheli, Giovanna Tedesco, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|July 13, 2002
Evaluation of the role of intestinal and liver metabolism in the conversion of two different ester prodrugs of sanfetrinem to the parent drug in vitro and in vivo using different rat tissues and a surgically prepared rat modelSimone Braggio, Alessia Ferrara, Matteo Sartori, et al.
Clinical Pharmacokinetics|May 4, 2023
Pharmacokinetics and Safety of Cotadutide, a GLP-1 and Glucagon Receptor Dual Agonist, in Individuals with Renal Impairment: A Single-Dose, Phase I, Bridging StudyGernot Klein, Marcella Petrone, Ye Yang, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 16, 2025
From In Vitro Efficacy to Long-Term HbA1c Response for GLP-1R/GlucagonR Agonism Using the 4GI-HbA1c Systems ModelRolien Bosch, Marcella Petrone, Rosalin Arends, et al.
Bioorganic & Medicinal Chemistry Letters|November 1, 2006
Isoindolone derivatives, a new class of 5-HT2C antagonists: synthesis and biological evaluationDieter Hamprecht, Fabrizio Micheli, Giovanna Tedesco, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 10, 2021
A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP-1 dual agonistRolien Bosch, Marcella Petrone, Rosalin Arends, et al.
British Journal of Pharmacology|February 25, 2024
Characterisation of cotadutide's dual GLP-1/glucagon receptor agonistic effects on glycaemic control using an in vivo human glucose regulation quantitative systems pharmacology modelRolien Bosch, Marcella Petrone, Rosalin Arends, et al.
Diabetes, Obesity & Metabolism|April 28, 2021
Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese participants of Asian descent with or without type 2 diabetesMichiko Asano, Akiko Sekikawa, Hyosung Kim, et al.
British Journal of Clinical Pharmacology|June 22, 2018
MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 studyPhilip D Ambery, Sebastian Klammt, Maximillian G Posch, et al.
Diabetologia|December 30, 2018
Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitusMeena Jain, Glenn Carlson, William Cook, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Bioorganic & Medicinal Chemistry Letters|November 3, 2006
5-HT2C antagonists based on fused heterotricyclic templates: design, synthesis and biological evaluationDieter Hamprecht, Fabrizio Micheli, Giovanna Tedesco, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|July 13, 2002
Evaluation of the role of intestinal and liver metabolism in the conversion of two different ester prodrugs of sanfetrinem to the parent drug in vitro and in vivo using different rat tissues and a surgically prepared rat modelSimone Braggio, Alessia Ferrara, Matteo Sartori, et al.
Clinical Pharmacokinetics|May 4, 2023
Pharmacokinetics and Safety of Cotadutide, a GLP-1 and Glucagon Receptor Dual Agonist, in Individuals with Renal Impairment: A Single-Dose, Phase I, Bridging StudyGernot Klein, Marcella Petrone, Ye Yang, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 16, 2025
From In Vitro Efficacy to Long-Term HbA1c Response for GLP-1R/GlucagonR Agonism Using the 4GI-HbA1c Systems ModelRolien Bosch, Marcella Petrone, Rosalin Arends, et al.
Bioorganic & Medicinal Chemistry Letters|November 1, 2006
Isoindolone derivatives, a new class of 5-HT2C antagonists: synthesis and biological evaluationDieter Hamprecht, Fabrizio Micheli, Giovanna Tedesco, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 10, 2021
A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP-1 dual agonistRolien Bosch, Marcella Petrone, Rosalin Arends, et al.
British Journal of Pharmacology|February 25, 2024
Characterisation of cotadutide's dual GLP-1/glucagon receptor agonistic effects on glycaemic control using an in vivo human glucose regulation quantitative systems pharmacology modelRolien Bosch, Marcella Petrone, Rosalin Arends, et al.
Diabetes, Obesity & Metabolism|April 28, 2021
Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese participants of Asian descent with or without type 2 diabetesMichiko Asano, Akiko Sekikawa, Hyosung Kim, et al.
British Journal of Clinical Pharmacology|June 22, 2018
MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 studyPhilip D Ambery, Sebastian Klammt, Maximillian G Posch, et al.
Diabetologia|December 30, 2018
Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitusMeena Jain, Glenn Carlson, William Cook, et al.
Pageof 3